FDA Approves Enhertu for Early-Stage HER2+ Breast Cancer in Curative Settings
Trastuzumab deruxtecan wins two new FDA approvals for early HER2+ breast cancer, showing dramatic survival gains over standard therapy.
Summary
The FDA has approved trastuzumab deruxtecan (Enhertu) for two new uses in early-stage HER2-positive breast cancer — before and after surgery. In the neoadjuvant (pre-surgery) setting, it achieved a 67.3% pathologic complete response rate versus 56.3% for standard chemotherapy. In the adjuvant (post-surgery) setting, 92.4% of patients remained disease-free at 3 years compared to 83.7% with the previous standard drug. These approvals mark a significant shift in how aggressive early-stage breast cancer is treated, potentially reducing recurrence risk at the earliest possible stage. The drug is already widely used in advanced breast cancer, and these new indications expand its reach into potentially curative treatment strategies.
Detailed Summary
Trastuzumab deruxtecan, sold as Enhertu and developed by AstraZeneca and Daiichi Sankyo, has received two new FDA approvals targeting early-stage HER2-positive breast cancer — a historically aggressive subtype. These approvals mark a meaningful expansion from its existing use in metastatic disease into settings where the goal is outright cure, not just disease management.
The first approval covers neoadjuvant treatment, meaning the drug is given before surgery. In the DESTINY-Breast11 trial, patients receiving T-DXd followed by a standard taxane-trastuzumab-pertuzumab regimen achieved a pathologic complete response rate of 67.3%, compared to 56.3% with a dose-dense chemotherapy regimen. Pathologic complete response — no detectable cancer at surgery — is a strong predictor of long-term survival in breast cancer.
The second approval addresses adjuvant treatment, given after surgery to patients who had residual disease despite neoadjuvant therapy. The DESTINY-Breast05 trial showed that at 3 years, 92.4% of T-DXd patients were alive and free of invasive disease, versus 83.7% for those receiving trastuzumab emtansine — the previous standard. The hazard ratio of 0.47 represents a 53% reduction in the risk of invasive disease or death.
For health-conscious readers focused on longevity and disease prevention, these findings highlight the growing power of precision oncology. HER2-positive breast cancer, once among the most feared diagnoses, is increasingly controllable when targeted therapies are applied early and accurately. Companion diagnostics approved alongside these indications help identify the right patients.
Caveats include a known safety profile requiring monitoring: interstitial lung disease, neutropenia, and cardiac dysfunction are documented risks. These approvals apply specifically to HER2-positive patients, not all breast cancer subtypes. Long-term follow-up data beyond 3 years will be important to confirm durable survival benefits.
Key Findings
- T-DXd achieved 67.3% pathologic complete response in early HER2+ breast cancer vs 56.3% for standard chemo.
- At 3 years post-surgery, 92.4% of T-DXd patients were disease-free vs 83.7% on prior standard drug Kadcyla.
- Hazard ratio of 0.47 means T-DXd cut risk of invasive disease or death by 53% in the adjuvant setting.
- FDA approved companion diagnostics to ensure only eligible HER2-positive patients receive treatment.
- Approvals expand T-DXd into curative-intent settings, shifting it beyond its existing metastatic cancer uses.
Methodology
This is a news report from MedPage Today summarizing two FDA drug approvals supported by Phase III clinical trial data from DESTINY-Breast11 and DESTINY-Breast05. MedPage Today is a credible, clinician-focused medical news outlet. Evidence basis is regulatory-grade randomized controlled trial data with statistically significant outcomes.
Study Limitations
The article is a news summary, not a primary research publication — full trial data and safety tables require review of original DESTINY-Breast publications. Three-year follow-up is promising but longer-term survival data are still maturing. Approval applies only to HER2-positive patients; HER2-low or HER2-negative patients are not eligible under these indications.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.